AFT Pharmaceuticals registers intravenous Maxigesic with TGA

Company News

by Rachael Jones

AFT Pharmaceuticals (ASX:AFP) has successfully registered the intravenous form of its successful ‘Maxigesic’ pain relief medication with the Therapeutic Goods Administration.

Sales of Maxigesic IV® are now expected to take place in the current financial year.

This registration clears the way for regulatory filings in other countries such as Mexico, South East Asia, Korea and the Middle East.

All these countries rely upon registration by key global reference regulators such as the TGA in Australia.

Maxigesic IV has been developed as a line extension to Maxigesic tablets, for post-operative pain relief in hospitals where patients cannot take an oral pain relief medicine.

Shares in AFT Pharmaceuticals (ASX:AFP) last traded at $3.09.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.